➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Medtronic
Mallinckrodt
Express Scripts
Johnson and Johnson

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MERIDIA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Meridia

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00234832 ↗ A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients Completed Abbott Phase 3 2003-01-01 The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event.
NCT00234988 ↗ A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects. Completed Abbott Phase 4 2004-06-01 The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects.
NCT00261911 ↗ A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety. Completed Abbott Phase 3 2000-07-01 The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.
NCT00402077 ↗ A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects Completed AstraZeneca Phase 2 2006-11-01 This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Meridia

Condition Name

Condition Name for Meridia
Intervention Trials
Obesity 13
Binge Eating 2
Binge Eating Disorder 1
Weight Loss 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Meridia
Intervention Trials
Weight Loss 4
Overweight 3
Bulimia 3
Binge-Eating Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Meridia

Trials by Country

Trials by Country for Meridia
Location Trials
United States 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Meridia
Location Trials
New York 3
California 2
Arizona 2
Illinois 2
Connecticut 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Meridia

Clinical Trial Phase

Clinical Trial Phase for Meridia
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Meridia
Clinical Trial Phase Trials
Completed 11
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Meridia

Sponsor Name

Sponsor Name for Meridia
Sponsor Trials
Abbott 7
AstraZeneca 2
Yale University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Meridia
Sponsor Trials
Industry 10
Other 4
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKinsey
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.